Home / Innere Medizin / Hämatologie und internistische Onkologie / ESMO 2019: RCC – „Abwarten, was Immuntherapie im adjuvanten Setting bringt“
OÄ Dr. Ursula Vogl

ESMO 2019: RCC – „Abwarten, was Immuntherapie im adjuvanten Setting bringt“

OÄ Dr. Ursula Vogl, Barmherzige Schwestern Krankenhaus Wien, über Rückschritte bei der adjuvanten Behandlung und bereits erprobte und neue Ansätze im metastasierten Setting.

Interviewpartner:

Redaktion:

Produktion:

Im Video diskutierte Abstracts:

Eisen TQ et al. Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An international, randomised double-blind phase III trial led by the MRC CTU at UCL. #LBA56

Lee CH et al. ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC). #LBA54

Grimm MO et al. Tailored immunotherapy approach with nivolumab in advanced renal cell carcinoma (TITAN-RCC). #LBA57

Lee CH et al. Phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis. #1187PD

McDermott DF et al. Safety and efficacy of the oral CXCR4 inhibitor X4P-001 + axitinib in advanced renal cell carcinoma patients: An analysis of subgroup responses by prior treatment. #1186PD

LOGIN